针对精氨酸微环境的代谢工程增强CAR-T细胞增殖与治疗活性
血液系统和实体肿瘤分解代谢精氨酸以驱动细胞增殖,由此形成的低精氨酸微环境会损害嵌合抗原受体T细胞(CAR-T)的增殖并限制其疗效。研究发现T细胞因精氨酸再合成酶表达低而对低精氨酸敏感,通过表达功能性ASS或OTC酶可增强CAR-T细胞增殖且不损失细胞毒性或增加耗竭,在体内增强对白血病或实体瘤负荷的清除。
要点
- 低精氨酸微环境损害CAR-T细胞增殖并限制其疗效
- T细胞因ASS和OTC表达低而对低精氨酸敏感
- 表达ASS或OTC的代谢工程化CAR-T细胞体内增强肿瘤清除
核心结论
- 表达功能性ASS或OTC酶的代谢工程化CAR-T细胞可增强增殖和体内肿瘤清除,是首个增强CAR-T细胞治疗的代谢修饰。
研究设计与样本
- 研究涉及T细胞被重新工程化以表达功能性ASS或OTC酶,并与不同嵌合抗原受体组合,在体外和体内评估。
主要发现
- 酶修饰增加CAR-T细胞增殖,且无CAR细胞毒性损失或耗竭增加。
- 在体内,酶修饰的CAR-T细胞增强对白血病或实体瘤负荷的清除。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematological and solid cancers catabolize the semiessential amino acid arginine to drive cell proliferation. However, the resulting low arginine microenvironment also impairs chimeric antigen receptor T cells (CAR-T) cell proliferation, limiting their efficacy in clinical trials against hematological and solid malignancies. T cells are susceptible to the low arginine microenvironment because of the low expression of the arginine resynthesis enzymes argininosuccinate synthase (ASS) and ornithine transcarbamylase (OTC). We demonstrate that T cells can be reengineered to express functional ASS or OTC enzymes, in concert with different chimeric antigen receptors. Enzyme modifications increase CAR-T cell proliferation, with no loss of CAR cytotoxicity or increased exhaustion. In vivo, enzyme-modified CAR-T cells lead to enhanced clearance of leukemia or solid tumor burden, providing the first metabolic modification to enhance CAR-T cell therapies.
引用
- Fultang L, Booth S, Yogev O, et al. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood. 2020. PMID: 32573723. doi:10.1182/blood.2019004500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。